表紙
市場調查報告書

移植用HLA型檢測的全球市場:PCR (SSO、SSP、即時),定序 (NGS、Sanger法),嵌合體,抗體篩檢 - 至2025年的預測

HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User - Global Forecast to 2025

出版商 MarketsandMarkets 商品編碼 931149
出版日期 內容資訊 英文 194 Pages
訂單完成後即時交付
價格
移植用HLA型檢測的全球市場:PCR (SSO、SSP、即時),定序 (NGS、Sanger法),嵌合體,抗體篩檢 - 至2025年的預測 HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User - Global Forecast to 2025
出版日期: 2020年03月30日內容資訊: 英文 194 Pages
簡介

全球移植用HLA型檢測市場規模預測將從2019年的6億5,600萬美元,到2025年達到9億6,800萬美元,在預測期間內預計將以年複合成長率6.7%的速度成長。移植用HLA型檢測產品的需求,由於以HLA型檢測領域中技術進步及研究活動為目的公民營資金的增加等,而預計擴大。各終端用戶中,獨立參考實驗室區隔,由於診斷實驗室的迅速現代化和對自動化,及醫藥品 & 生物科技企業將R&D活動外部委託給獨立參考實驗室的數量增加,2019年構成了最大的市場佔有率。各技術中,分子化驗技術,由於所需時間短,次序的有效性高,即時樣品分析的優點,2019年構成最大的市場佔有率。各地區中,2019年北美構成最大的市場佔有率,其次是歐洲。

本報告提供全球移植用HLA型檢測市場相關調查分析,各市場區隔、各地區的市場分析與預測,市場發展的影響要素,競爭環境,及主要企業等相關的系統性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 移植用HLA型檢測市場概要
  • 移植用HLA型檢測市場:各技術
  • 移植用HLA型檢測市場地區分析:各用途
  • 亞太地區的移植用HLA型檢測市場:各終端用戶
  • 移植用HLA型檢測市場地區分析:各產品、服務
  • 移植用HLA型檢測市場:各國

第5章 市場概要

  • 簡介
  • 市場動態
    • 主要的促進因素
    • 主要的阻礙因素
    • 主要市場機會
    • 主要市場課題

第6章 移植用HLA型檢測市場:各產品、服務

  • 簡介
  • 試劑、消耗品
  • 設備
  • 軟體、服務

第7章 移植用HLA型檢測市場:各技術

  • 簡介
  • 分子化驗技術
    • PCR型分子化驗
    • 定序型分子化驗
  • 非分子化驗技術
    • 使用了DNA型HLA型檢測手法替代非分子化驗技術預計妨礙市場成長

第8章 移植用HLA型檢測市場:各用途

  • 簡介
  • 診斷用途
    • 抗體篩檢
    • 嵌合體監測
    • 其他的用途
  • 研究用
    • 器官捐贈者和移植接收者的交叉配對試驗的新遺傳基因 & 生物標記識別的增加,促進市場成長

第9章 移植用HLA型檢測市場:各終端用戶

  • 簡介
  • 獨立型參考實驗室
  • 醫院、移植中心
  • 研究所、大學機關

第10章 移植用HLA型檢測市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第11章 競爭情形

  • 概要
  • 市場佔有率分析
  • 競爭模式
  • 競爭領導製圖

第12章 企業簡介

  • THERMO FISHER SCIENTIFIC
  • F. HOFFMAN-LA ROCHE LIMITED
  • QIAGEN
  • IMMUCOR
  • ABBOTT LABORATORIES INC.
  • CAREDX, INC.
  • ILLUMINA
  • BIO-RAD LABORATORIES
  • ALPHA BIOTECH, LTD.
  • GENDX
  • LUMINEX
  • BIOFORTUNA
  • OMIXON
  • CREATIVE BIOLABS
  • TBG DIAGNOSTICS LIMITED
  • 其他企業
    • BAG HEALTHCARE
    • TaKaRa BIO
    • HISTOGENETICS LLC
    • PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
    • HANSA BIOPHARMA AB

第13章 附錄

目錄
Product Code: BT 7584

"The global HLA typing for transplants market is projected to grow at a CAGR of 6.7% during the forecast period."

The global HLA typing for the transplants market is expected to reach USD 968 million by 2025 from USD 656 million in 2019, at a CAGR of 6.7%. The demand for HLA typing products for transplant is expected to grow due to technological advancements in the field of HLA typing and increasing public-private funding for target research activities. The HLA typing for the transplants market is segmented on the product, technology, application, end-user, and region.

"The independent reference laboratories segment accounted for the largest share of the HLA typing for transplants market, by end-user, in 2019."

Based on end user, the HLA typing for transplants market is segmented into independent reference laboratories, hospitals & transplant centers, and research laboratories & academic institutes. In 2019, independent reference laboratories accounted for the largest share of the HLA typing for transplants market due to rapid modernization and automation in diagnostic laboratories, the growing number of R&D activities outsourced by pharmaceutical & biotechnology companies to independent reference laboratories.

"The molecular assay technologies segment accounted for the largest share of the HLA typing for transplants market, by technology, in 2019."

The HLA typing for transplants market, by technology, is segmented into molecular (PCR-based assay and sequencing-based assay technologies) and non-molecular assay technologies. In 2019, the molecular assay technologies segment accounted for the largest share of the HLA typing for transplants market due to the benefits of molecular assays such as low turnaround times, high procedural efficacy, and real-time sample analysis.

"North America accounted for the largest share of the HLA typing for transplants market in 2019."

North America accounted for the largest share of the HLA typing for transplants market in 2019, followed by Europe. This can primarily be attributed to the wide availability of advanced transplant diagnostic technologies (includes HLA typing), well-established distribution channels, and significant public awareness about the clinical benefits of diagnostic products in risk assessment for donors and recipients during transplantations.

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1 (48%), Tier 2 (36%), and Tier 3 (16%)
  • By Designation: C-level (10%), Director-level (14%), and Others (76%)
  • By Region: North America (40%), Europe (32%), APAC (20%), and RoW (8%)

Some of the prominent players in the HLA typing for transplants market are: Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina (US), CareDx, Inc. (US), Immucor, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Luminex (US), Biofortuna (UK), Takara Bio (Japan), and Omixon (Hungary).

Research Coverage:

This report studies the HLA typing for transplants market based on product, technology, application, end-user, and region. It studies major factors (such as drivers and restraints) affecting market growth. The report also analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. It the the with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.

Key Benefits of Buying the Report:

This report focuses on various levels of analysis-industry trends, market shares of top players, and company profiles, which together form basic views. It also analyzes the competitive landscapeusers emerging segments of the HLA typing for transplants market; and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY USED FOR THE STUDY
  • 1.5 MAJOR MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Secondary sources
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
    • 2.2.2 PROCEDURE-BASED MARKET ESTIMATION
    • 2.2.3 PRIMARY RESEARCH VALIDATION
  • 2.3 DATA TRIANGULATION
  • 2.4 RESEARCH ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 HLA TYPING FOR TRANSPLANTS MARKET OVERVIEW
  • 4.2 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY
  • 4.3 REGIONAL ANALYSIS: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION
  • 4.4 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2019
  • 4.5 REGIONAL ANALYSIS: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE
  • 4.6 HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 KEY MARKET DRIVERS
      • 5.2.1.1 Increasing number of transplant procedures
      • 5.2.1.2 Technological advancements in the field of HLA typing
      • 5.2.1.3 Increasing public-private funding for target research activities
    • 5.2.2 KEY MARKET RESTRAINTS
      • 5.2.2.1 High costs of molecular tests used for HLA typing procedures
      • 5.2.2.2 Limited reimbursements for target procedures
    • 5.2.3 KEY MARKET OPPORTUNITIES
      • 5.2.3.1 Rising adoption of cross-matching and chimerism testing during pre- & post-transplantation
      • 5.2.3.2 Technological shift from non-molecular serological assays to gene-based HLA profiling
      • 5.2.3.3 Increasing public awareness about organ donation and transplantation across emerging countries
    • 5.2.4 KEY MARKET CHALLENGES
      • 5.2.4.1 Significant gap between the number of organ donors and organs required annually

6 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
  • 6.2 REAGENTS & CONSUMABLES
    • 6.2.1 INCREASING PATIENT EMPHASIS ON EFFECTIVE PATIENT PROFILING DURING ORGAN TRANSPLANTATION TO DRIVE MARKET GROWTH
  • 6.3 INSTRUMENTS
    • 6.3.1 INCREASING PATIENT AWARENESS ABOUT THE BENEFITS OFFERED BY GENOME-BASED PROFILING WILL SUPPORT MARKET GROWTH
  • 6.4 SOFTWARE & SERVICES
    • 6.4.1 RISING DEMAND FOR INNOVATIVE HLA TYPING SOFTWARE DURING THE DETECTION OF SPECIFIC ALLELES IS SUPPORTING MARKET GROWTH

7 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
  • 7.2 MOLECULAR ASSAY TECHNOLOGIES
    • 7.2.1 PCR-BASED MOLECULAR ASSAYS
      • 7.2.1.1 Sequence-specific oligonucleotide-PCR
        • 7.2.1.1.1 Growing awareness about the benefits offered by SSO-PCR among medical professionals to drive market growth
      • 7.2.1.2 Sequence-specific primer-PCR
        • 7.2.1.2.1 Growing public-private investments for research activities to support market growth
      • 7.2.1.3 Real-time PCR
        • 7.2.1.3.1 High cost of real-time PCR and procedural complexity to hamper market growth
      • 7.2.1.4 Other PCR-based molecular assays
    • 7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
      • 7.2.2.1 Sanger sequencing
        • 7.2.2.1.1 Growing demand for high-throughput DNA sequencers to drive market growth
      • 7.2.2.2 Next-generation sequencing
        • 7.2.2.2.1 Expansion in the application horizons of NGS in the field of tissue typing to support market growth
      • 7.2.2.3 Other sequencing-based molecular assays
  • 7.3 NON-MOLECULAR ASSAY TECHNOLOGIES
    • 7.3.1 REPLACEMENT OF NON-MOLECULAR ASSAY TECHNIQUES WITH DNA-BASED HLA TYPING PROCEDURES IS EXPECTED TO HAMPER MARKET GROWTH

8 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 DIAGNOSTIC APPLICATIONS
    • 8.2.1 ANTIBODY SCREENING
      • 8.2.1.1 Rising number of recipients for transplant procedures to drive market growth
    • 8.2.2 CHIMERISM MONITORING
      • 8.2.2.1 Rising trend of personalized transplant medicine for effective post-procedural clinical risk management to drive market growth
    • 8.2.3 OTHER APPLICATIONS
  • 8.3 RESEARCH APPLICATIONS
    • 8.3.1 INCREASING IDENTIFICATION OF NEW GENES & BIOMARKERS IN DONOR-RECIPIENT CROSS MATCH WILL DRIVE THE MARKET GROWTH

9 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 INDEPENDENT REFERENCE LABORATORIES
    • 9.2.1 INCREASING NUMBER OF PREVENTIVE GENOMIC CLINICS TO DRIVE MARKET GROWTH
  • 9.3 HOSPITALS & TRANSPLANT CENTERS
    • 9.3.1 HEALTHCARE CONSOLIDATION AND ESTABLISHMENT OF NEW HOSPITALS TO SUPPORT MARKET GROWTH
  • 9.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
    • 9.4.1 GROWING AWARENESS ABOUT THE RESEARCH APPLICATIONS IN TRANSPLANT REJECTION MONITORING TO DRIVE MARKET GROWTH

10 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 US
      • 10.2.1.1 Ongoing technological advancements in the field of HLA typing to drive market growth in the US
    • 10.2.2 CANADA
      • 10.2.2.1 Growing availability of HLA typing products to support market growth in Canada
  • 10.3 EUROPE
    • 10.3.1 GERMANY
      • 10.3.1.1 Germany accounted for the largest share of the European market
    • 10.3.2 UK
      • 10.3.2.1 Rising number of transplantation procedures to drive market growth in the UK
    • 10.3.3 FRANCE
      • 10.3.3.1 Adoption of molecular diagnostic techniques for donor-recipient compatibility testing is increasing in France
    • 10.3.4 ITALY
      • 10.3.4.1 Sluggish growth in the Italian healthcare sector in the last few years to restrain market growth
    • 10.3.5 SPAIN
      • 10.3.5.1 Rising number of solid organ transplantation procedures to drive market growth in Spain
    • 10.3.6 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 JAPAN
      • 10.4.1.1 Significant growth in chronic disease prevalence to support market growth in Japan
    • 10.4.2 CHINA
      • 10.4.2.1 Healthcare infrastructure improvements to support market growth in China
    • 10.4.3 INDIA
      • 10.4.3.1 Increasing number of transplantation procedures to drive market growth in India
    • 10.4.4 AUSTRALIA
      • 10.4.4.1 Rising number of solid organ transplantation procedures to support market growth in Australia
    • 10.4.5 SOUTH KOREA
      • 10.4.5.1 Government initiatives to introduce medical coverage for transplantation to support market growth in South Korea
    • 10.4.6 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 BRAZIL
      • 10.5.1.1 Brazil accounted for the largest share of the LATAM market
    • 10.5.2 MEXICO
      • 10.5.2.1 Rising medical tourism to support market growth in Mexico
    • 10.5.3 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST AND AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 MARKET SHARE ANALYSIS
  • 11.3 COMPETITIVE SCENARIO
    • 11.3.1 KEY PRODUCT LAUNCHES AND APPROVALS
    • 11.3.2 KEY AGREEMENTS AND COLLABORATIONS
    • 11.3.3 KEY ACQUISITIONS
    • 11.3.4 KEY EXPANSIONS
  • 11.4 COMPETITIVE LEADERSHIP MAPPING
    • 11.4.1 VISIONARY LEADERS
    • 11.4.2 INNOVATORS
    • 11.4.3 DYNAMIC DIFFERENTIATORS
    • 11.4.4 EMERGING COMPANIES

12 COMPANY PROFILES

(Business overview, Products offered, Recent developments, MNM view)*

  • 12.1 THERMO FISHER SCIENTIFIC
  • 12.2 F. HOFFMAN-LA ROCHE LIMITED
  • 12.3 QIAGEN
  • 12.4 IMMUCOR
  • 12.5 ABBOTT LABORATORIES INC.
  • 12.6 CAREDX, INC.
  • 12.7 ILLUMINA
  • 12.8 BIO-RAD LABORATORIES
  • 12.9 ALPHA BIOTECH, LTD.
  • 12.10 GENDX
  • 12.11 LUMINEX
  • 12.12 BIOFORTUNA
  • 12.13 OMIXON
  • 12.14 CREATIVE BIOLABS
  • 12.15 TBG DIAGNOSTICS LIMITED
  • 12.16 OTHER COMPANIES
    • 12.16.1 BAG HEALTHCARE
    • 12.16.2 TAKARA BIO
    • 12.16.3 HISTOGENETICS LLC
    • 12.16.4 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
    • 12.16.5 HANSA BIOPHARMA AB

Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR THE DEVELOPMENT OF HLA TYPING PRODUCTS FOR TRANSPLANT PROCEDURES, 2015-2018
  • TABLE 2: COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2017)
  • TABLE 3: APPLICABLE CODES FOR HLA TYPING
  • TABLE 4: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 5: REAGENTS & CONSUMABLES MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 6: INSTRUMENTS MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 7: SOFTWARE & SERVICES MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 8: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 9: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 10: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY PRODUCT, 2017-2025 (USD MILLION)
  • TABLE 11: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 12: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 13: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 14: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 15: PCR-BASED MOLECULAR ASSAYS MARKET, BY PRODUCT, 2017-2025 (USD MILLION)
  • TABLE 16: PCR-BASED MOLECULAR ASSAYS MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 17: PCR-BASED MOLECULAR ASSAYS MARKET, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 18: PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 19: SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 20: SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 21: REAL-TIME PCR MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 22: OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 23: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 24: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY PRODUCT, 2017-2025 (USD MILLION)
  • TABLE 25: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 26: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 27: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 28: SANGER SEQUENCING MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 29: NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 30: OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 31: NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY PRODUCT, 2017-2025 (USD MILLION)
  • TABLE 32: NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 33: NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 34: NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 35: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 36: DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 37: DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 38: ANTIBODY SCREENING MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 39: CHIMERISM MONITORING MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 40: OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 41: RESEARCH APPLICATIONS MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 42: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 43: INDEPENDENT REFERENCE LABORATORIES MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 44: HOSPITALS & TRANSPLANT CENTERS MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 45: RESEARCH LABORATORIES & ACADEMIC INSTITUTES MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 46: HLA TYPING FOR TRANSPLANTS MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 47: NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017-2025 (USD MILLION)
  • TABLE 48: NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 49: NORTH AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 50: NORTH AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 51: NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 52: NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 53: NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 54: US: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 55: US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 56: US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 57: CANADA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 58: CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 59: CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 60: EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017-2025 (USD MILLION)
  • TABLE 61: EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 62: EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 63: EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 64: EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 65: EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 66: EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 67: NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN GERMANY, 2015 VS. 2018
  • TABLE 68: GERMANY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 69: GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 70: GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 71: NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN THE UK, 2015 VS. 2018
  • TABLE 72: UK: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 73: UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 74: UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 75: NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN FRANCE, 2015 VS. 2018
  • TABLE 76: FRANCE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 77: FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 78: FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 79: NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN ITALY, 2015 VS. 2018
  • TABLE 80: ITALY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 81: ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 82: ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 83: NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN SPAIN, 2015 VS. 2018
  • TABLE 84: SPAIN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 85: SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 86: SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 87: ROE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 88: ROE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 89: ROE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 90: ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017-2025 (USD MILLION)
  • TABLE 91: ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 92: ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 93: ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 94: ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 95: ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 96: ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 97: JAPAN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 98: JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 99: JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 100: NUMBER OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN CHINA, 2013 VS. 2015
  • TABLE 101: CHINA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 102: CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 103: CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 104: NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN INDIA, 2015 VS. 2018
  • TABLE 105: INDIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 106: INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 107: INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 108: NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN AUSTRALIA, 2015 VS. 2018
  • TABLE 109: AUSTRALIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 110: AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 111: AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 112: SOUTH KOREA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 113: SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 114: SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 115: ROAPAC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 116: ROAPAC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 117: ROAPAC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 118: LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017-2025 (USD MILLION)
  • TABLE 119: LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 120: LATAM: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 121: LATAM: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 122: LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 123: LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 124: LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 125: NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN BRAZIL, 2015 VS. 2018
  • TABLE 126: BRAZIL: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 127: BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 128: BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 129: NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN MEXICO, 2015 VS. 2018
  • TABLE 130: MEXICO: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 131: MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 132: MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 133: ROLATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 134: ROLATAM: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 135: ROLATAM: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 136: MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 137: MEA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 138: MEA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 139: MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 140: MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 141: MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017-2025 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARIES: GLOBAL HLA TYPING FOR TRANSPLANTS MARKET
  • FIGURE 3: RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 4: MARKET SIZE ESTIMATION: HLA TYPING FOR TRANSPLANTS MARKET
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY PRODUCT & SERVICE, 2019 VS. 2025
  • FIGURE 7: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2019 VS. 2025 (USD MILLION)
  • FIGURE 8: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2019 VS. 2025 (USD MILLION)
  • FIGURE 9: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2019 VS. 2025 (USD MILLION)
  • FIGURE 10: GEOGRAPHICAL SNAPSHOT OF THE HLA TYPING FOR TRANSPLANTS MARKET
  • FIGURE 11: INCREASING NUMBER OF TRANSPLANTATION PROCEDURES TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
  • FIGURE 12: PCR-BASED MOLECULAR ASSAYS TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
  • FIGURE 13: ANTIBODY SCREENING AND CHIMERISM MONITORING SEGMENTS TO WITNESS HIGH GROWTH IN THE ASIA PACIFIC MARKET
  • FIGURE 14: INDEPENDENT REFERENCE LABORATORIES ARE THE LARGEST END USERS IN THE APAC MARKET
  • FIGURE 15: NORTH AMERICA IS ESTIMATED TO BE THE LARGEST MARKET FOR ALL PRODUCT & SERVICE SEGMENTS IN THE HLA TYPING FOR TRANSPLANTS MARKET IN 2019
  • FIGURE 16: MARKET IN CHINA AND INDIA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 17: HLA TYPING FOR TRANSPLANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 18: NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
  • FIGURE 19: SOLID ORGAN TRANSPLANTATIONS PERFORMED IN THE US, 2015-2019
  • FIGURE 20: SOLID ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN CANADA, 2015-2018
  • FIGURE 21: EUROPE: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
  • FIGURE 22: ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
  • FIGURE 23: NUMBER OF SOLID ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN JAPAN, 2015-2018
  • FIGURE 24: PRODUCT LAUNCHES AND ENHANCEMENTS WERE THE KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2016 TO 2019
  • FIGURE 25: THERMO FISHER SCIENTIFIC DOMINATED THE GLOBAL HLA TYPING FOR TRANSPLANTS MARKET IN 2019
  • FIGURE 26: HLA TYPING FOR TRANSPLANTS MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2019
  • FIGURE 27: THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018)
  • FIGURE 28: F. HOFFMAN-LA ROCHE LIMITED: COMPANY SNAPSHOT (2018)
  • FIGURE 29: QIAGEN: COMPANY SNAPSHOT (2018)
  • FIGURE 30: IMMUCOR: COMPANY SNAPSHOT (2016)
  • FIGURE 31: ABBOTT LABORATORIES INC.: COMPANY SNAPSHOT (2018)
  • FIGURE 32: CAREDX: COMPANY SNAPSHOT (2018)
  • FIGURE 33: ILLUMINA: COMPANY SNAPSHOT (2018)
  • FIGURE 34: BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2018)
  • FIGURE 35: LUMINEX: COMPANY SNAPSHOT (2018)
  • FIGURE 36: TBG DIAGNOSTICS LIMITED: COMPANY SNAPSHOT (2018)